MEI Pharma (MEIP) and Kyowa Kirin Reports Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. IVBIY
9. SPY
10. FIX

Go back to MEI Pharma (MEIP) and Kyowa Kirin Reports Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

November 30, 2021 7:00 AM EST

Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response

9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event

MEI to Host Webcast Today at 8:00am Eastern Time

SAN DIEGO & TOKYO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced... More